DataVXACS Applied Materials & InterfacesPaper
journal article·2023-04-05

DNA Supramolecular Hydrogel-Enabled Sustained Delivery of Metformin for Relieving Osteoarthritis

Chao Zhang, Hong Huang, Jianmao Chen, Tingting Zuo, Qianhua Ou, Guangfeng Ruan, Jian He, Changhai Ding

ACS Applied Materials & Interfaces· Volume 15· Issue 13
Publisher page
Source abstract

Abstract

Osteoarthritis (OA) is a musculoskeletal disorder affecting ∼500 million people worldwide. Metformin (MET), as an oral hypoglycemic drug approved by the Food and Drug Administration, has displayed promising potential for treating OA. Nonetheless, in the articular cavity, MET suffers from rapid clearance and cannot circumvent the severe inflammatory environment, greatly confining the therapeutic efficacy. Herein, DNA supramolecular hydrogel (DSH) has been utilized as a sustained drug delivery vehicle for MET to treat OA, which dramatically prolonged the retention time of MET in the articular cavity from 3 to 14 days and simultaneously exerted a greater anti-inflammatory effect. Our delivery platform, termed MET@DSH, better protects cartilage than single-agent MET. Additionally, the corresponding molecular mechanisms underlying the therapeutic effects were also analyzed. We anticipate this DNA supramolecular hydrogel-enabled sustained drug delivery and anti-inflammatory strategy will reshape the current landscape of OA treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

Polymers

OpenAlex topics: Osteoarthritis Treatment and Mechanisms · RNA Interference and Gene Delivery · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Clinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China

Department of Rheumatology and Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China

Centre of Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China

College of Biological and Geographical Sciences, Yili Normal University, Yining, Xingjiang 835000, China

Clinical Research Centre, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong 510180, China

Department of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia

Funding

National Natural Science Foundation of China · Guangdong Basic and Applied Basic Research Foundation · Guangzhou Basic and Applied Basic Research Foundation

References (32)

Show source-provided references
1. 10.1016/S0140-6736(19)30417-910.1016/S0140-6736(19)30417-9 ↗
2. 10.1001/jama.2020.2217110.1001/jama.2020.22171 ↗
3. 10.1038/nrdp.2016.7210.1038/nrdp.2016.72 ↗
4. 10.1038/boneres.2016.4410.1038/boneres.2016.44 ↗
5. 10.1111/1756-185X.1425510.1111/1756-185X.14255 ↗
6. 10.2147/CLEP.S30936410.2147/CLEP.S309364 ↗
7. 10.2196/3779010.2196/37790 ↗
8. 10.1016/j.semarthrit.2022.15207010.1016/j.semarthrit.2022.152070 ↗
9. 10.3390/cells1119301210.3390/cells11193012 ↗
10. 10.1016/j.freeradbiomed.2017.11.02110.1016/j.freeradbiomed.2017.11.021 ↗
11. 10.1016/j.joca.2022.06.01010.1016/j.joca.2022.06.010 ↗
12. 10.1136/annrheumdis-2019-21671310.1136/annrheumdis-2019-216713 ↗
13. 10.1016/j.nano.2020.10221010.1016/j.nano.2020.102210 ↗
14. 10.1002/advs.20220433010.1002/advs.202204330 ↗
15. 10.1002/chem.20210014910.1002/chem.202100149 ↗
16. 10.1021/jacs.9b1076510.1021/jacs.9b10765 ↗
17. 10.1021/jacs.2c0783010.1021/jacs.2c07830 ↗
18. 10.1002/adma.20210475810.1002/adma.202104758 ↗
19. 10.1021/acs.accounts.6b0052410.1021/acs.accounts.6b00524 ↗
20. 10.1002/anie.20220252010.1002/anie.202202520 ↗
21. 10.1016/j.ymeth.2008.01.00610.1016/j.ymeth.2008.01.006 ↗
22. 10.1038/nprot.2008.9510.1038/nprot.2008.95 ↗
23. 10.3389/fgene.2019.0133510.3389/fgene.2019.01335 ↗
24. 10.1038/nrrheum.2010.21310.1038/nrrheum.2010.213 ↗
25. 10.1016/j.intimp.2022.10933810.1016/j.intimp.2022.109338 ↗
26. 10.1016/j.jconrel.2022.04.03710.1016/j.jconrel.2022.04.037 ↗
27. 10.1016/j.joca.2016.09.02510.1016/j.joca.2016.09.025 ↗
28. 10.3389/fimmu.2020.0011110.3389/fimmu.2020.00111 ↗
29. 10.3390/ijms2111383810.3390/ijms21113838 ↗
30. 10.1038/s41563-019-0462-910.1038/s41563-019-0462-9 ↗
31. 10.1016/j.neuropharm.2022.10930410.1016/j.neuropharm.2022.109304 ↗
32. 10.1001/jamanetworkopen.2022.4012610.1001/jamanetworkopen.2022.40126 ↗